HR Execs on the Move

HiberCell

www.hibercell.com

 
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.hibercell.com
  • 619 West 54th Street 8th Floor
    New York, NY USA 10019
  • Phone: 212.601.2800

Executives

Name Title Contact Details
Marie Stech
Director Human Resources Profile
Alan Rigby
Co Founder and President Profile

Similar Companies

Sapphire Biotech

Sapphire Biotech, Inc.`s diagnostic tool is being used to study the company`s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells.

Lumos Diagnostics

Lumos Diagnostics delivers custom diagnostic solutions by combining deep market insight with existing platform technologies, assay development capability and regulated manufacturing experience.

Texcell NA

Texcell NA is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Annexon Biosciences

Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.

AmnioLife

AmnioLife Corporation is a biotechnology company focused on the development and commercialization of a unique biologic suite of products designed to address unmet and underserved market needs with applications across multiple surgical specialties. We are committed to the development of novel biotechnology and regenerative therapeutics, primarily derived from placental origin. Currently we have filed a US provisional patent application on our core technology, ProLifixTM, an acellular collagen matrix. The Company has over 60 years of experience in biologics manufacturing and comercializaiton, and is led by Chris Broderick who recently launched a neurological tissue transplant technology and was responsible for over $10M in trending global sales.